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Open access under the ElIf drug-resistant malaria mutants are less ﬁt than sensitive forms, they will wane over time when active
drug pressure is removed and the overall sensitivity to the drug may be restored. However, most studies
addressing this issue have been largely retrospective. Here, we undertook a predictive study, using
mutant rodent malaria parasites resistant to the Artemisinin combination treatment (ACT) version of
artesunate + meﬂoquine (ATN + MF) to gain insights about their ability to compete with ATN + MF-sensi-
tive forms in untreated hosts. Previously, Plasmodium chabaudi parasites resistant to ATN + MF were
selected in vivo through prolonged passaging in mice under increasing doses of the two drugs, and shown
to harbour duplication of the mdr1 gene. Here, the resistant parasite, AS-ATNMF1, was mixed with its
progenitor AS-ATN in different proportions and each mixture was injected into mice that were left
untreated. Absolute percentage parasitaemias and the proportion of each parasite were then monitored
by microscopy and proportional sequencing, respectively, every two days for a period of 14 days. AS-
ATNMF1 outperformed its progenitor AS-ATN over the whole sampling period regardless of the relative
starting proportion of each parasite clone. In order to assess if consecutive sub-inoculations could have
been responsible for the apparent ﬁtness gain of the resistant parasite, its growth was compared to that
of AS-ATN27P, a parasite which was passaged the same number of times as AS-ATNMF1, but left
untreated. Although small ﬂuctuations in the proportion of each parasite were observed through time,
the relative abundance of each on the last day of sampling (Day 14) was virtually identical to that of
the starting inoculum. We conclude that there is no ﬁtness cost associated with MDR1-associated
ATN + MF resistance in vivo. These observations offer the ﬁrst insights about the within-host dynamics
between ACT-resistant and -sensitive parasites in absence of drug pressure.
 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
It is generally accepted that mutations conferring drug resis-
tance are frequently deleterious in absence of drug pressure, trans-
lating in a reduction in the ability of the resistant organism to
compete with a sensitive one in untreated hosts (Anderson,
2005; Bottger and Springer, 2008). This is known as ﬁtness cost
and has been largely described in bacteria (Gagneux, 2009; Andersson
and Hughes, 2010).
In malaria, the view that drug-resistant parasites are less ﬁt
than sensitive ones, and as such, they should gradually disappear
from a given parasite pool along time if active drug selection is re-
moved, is commonly accepted (Babiker, 2009; Babiker et al., 2009).
Consequently, strategies of drug use that exploit the cost of resis-a Tropical e Saúde Pública,
razil. Tel.: +55 62 98150282;
).
sevier OA license.tance (such as drug ‘‘recycling’’) could play an important role as
an additional tool in the therapy-based ﬁght against malaria. The
best studied example is that of chloroquine (CQ), a drug that was
ofﬁcially abandoned for in vivo treatment of Plasmodium falciparum
in nearly all malaria-endemic countries during the last two dec-
ades, due to widespread resistance (reviewed in Sá et al. (2011)).
CQ resistance is known to be caused by point mutations in the P.
falciparum chloroquine resistance transporter, PfCRT, and to a les-
ser extent, in the P-glycoprotein homologue 1, commonly known
as PfMDR1 (reviewed in Valderramos and Fidock (2006)). The
withdrawal of CQ has thus provided a good setting under which
the ﬁtness consequences of drug resistance and resistance-
associated mutations in absence of drug pressure can be evaluated
in natural parasite populations. Most studies addressing the topic
have signposted a trend towards declining prevalence of CQ-
resistant parasites when active CQ pressure was removed, suggest-
ing resistance to the drug and corresponding mutations impose a
ﬁtness cost to the malaria parasite in natural infections (Kublin
et al., 2003; Mita et al., 2004; Laufer et al., 2006; Temu et al.,
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ever, the example of CQ may not be universally inferred, as has
been shown that the ﬁtness cost of resistance may be modest
(Costanzo and Hartl, 2011) and/or compensatory mutations may
be selected for, which restore the ﬁtness of mutant variants to that
of sensitive parasites (Walliker et al., 2005; Brown et al., 2010).
In face of increasing resistance to CQ and other antimalarial
drugs (such as sulphadoxine–pyrimethamine, artemisinin combi-
nation therapies (ACTs) are now the ofﬁcial ﬁrst-line treatments
of P. falciparum in most malaria endemic countries (WHO, 2011).
However, reports of emerging resistance to ACTs in Asia (Carrara
et al., 2009; Dondorp et al., 2009; Lim et al., 2010; Phyo et al.,
2012) have ﬂung fears that resistance may spread to, or evolve
independently in other areas of the malaria-endemic realm.
Resistance to the different component drugs of ACTs has been
associated with ampliﬁcation of MDR1 both in P. falciparum and
in rodent malaria parasites (Price et al., 1997, 1999, 2004; Pickard
et al., 2003; Alker et al., 2007; Wongsrichanalai and Meshnick,
2008; Lim et al., 2009; Rogers et al., 2009; Chavchich et al., 2010;
Chaijaroenkul et al., 2010; Ding et al., 2011; Borges et al., 2011).
In terms of parasite ﬁtness, predictive experimental studies in P.
falciparum where in vitro resistance to artemisinin derivatives or
meﬂoquine was evolved, have proposed that increase in copy num-
bers of the pfmdr1 gene is associated with detrimental effects on
the parasite’s survival (Preechapornkul et al., 2009; Chen et al.,
2010).
Although in vitro studies in P. falciparum as above provide infor-
mation that may be directly deduced in the context of human ma-
laria, they are unable to replicate the intricate interactions that
may drive ﬁtness evolution in vivo. The rodent malaria parasite
Plasmodium chabaudi represents an attractive experimental
in vivo model to study the direct consequences of drug resistance
on parasite ﬁtness. Apart from the fact that it allows working
in vivo, it also abrogates the confounding effects of genetic recom-
bination and diversity that may occur in natural infections.
In P. chabaudi, sensitive and resistant clones are isogenic apart
from the mutation(s) underlying the resistance phenotype (Carlton
et al., 2001). Mixed infections of each clone (sensitive and resis-
tant) can be established to examine whether either has a compet-
itive advantage over the other. The evolution of the relative
abundance of each clone in vivo can be measured along time in
the course of the infection, using proportional sequencing (PS) tar-
geting a genetic mutation which differentiates the two clones
(Hunt et al., 2005). PS has been used in such way to investigate
the ﬁtness costs of CQ and pyrimethamine (PYR) resistance in P.
chabaudi (Walliker et al., 2005).
During the course of previous work, P. chabaudi parasites resis-
tant to ATN + MF were evolved experimentally through prolonged
in vivo passaging in mice under increasing dosages of the two
drugs (Rodrigues et al., 2010). In order to gain insights on the ﬁt-
ness dynamics of ATN + MF resistance in absence of active drug
pressure, the growth of the resistant parasite, AS-ATNMF1, was
compared here with that of its progenitor AS-ATN in untreated
hosts.Fig. 1. Segment of the Plasmodium chabaudi AS lineage that was investigated in
present work. Clones of P. chabaudi that were used in this study with corresponding
drug phenotypes and copy number of the mdr1 gene are enclosed in the dotted
circle. (ATN, artesunate; CQ, chloroquine; MF, meﬂoquine; Pyr, pyrimethamine).2. Materials and methods
2.1. Parasite clones, maintenance, and growth assessment
Blood infected with different clones of P. chabaudi chabaudi AS
lineage was kept in liquid nitrogen and thawed on ice upon use.
Infected blood was inoculated intra-peritoneally (i.p.) into six-
to-eight weeks old CD1 male mice and parasite growth (%
parasitaemia) was observed along time through inspection of
Giemsa-stained blood smears by optical microscopy. The parasiteclones used in this study are part of the P. chabaudi AS lineage
(Carlton et al., 2001) comprising drug-resistant mutants previously
generated by the sequential passage of parasites in mice treated
with different drugs (Fig. 1).
In the present study, the following clones were used (Fig.1): (i)
AS-ATN, which displays low level resistance to artesunate (ATN),
but is sensitive to three daily doses of 40 mg/kg of ATN + 4 mg/kg
of meﬂoquine (MF) (Afonso et al., 2006; Rodrigues et al., 2010);
(ii) AS-ATNMF1, which was generated after twenty-seven sub-
inoculations of AS-ATN through mice under in vivo ATN + MF pres-
sure, and is resistant to three daily doses of 40 mg/kg of
ATN + 4 mg/kg of (MF) (Rodrigues et al., 2010) and (iii) AS-ATN27P,
a parasite that was obtained after twenty-seven sub-inoculations
(same number as AS-ATNMF1) of AS-ATN into untreated animals.
Both AS-ATN and AS-ATN27P have a single copy of the mdr1 gene,
whilst AS-ATNMF1 harbours two copies (Rodrigues et al., 2010,
Fig. 1).
All animal work was conducted according to relevant national
and international guidelines, after approval by the Ethics Commit-
tee of the Instituto de Higiene e Medicina Tropical of Lisbon, Portu-
gal, under PARECER 2/2006 from August 1st 2006.
2.2. DNA extraction
DNA samples were extracted from blood spots preserved in ﬁl-
ter paper as follows: blood samples were collected by small
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Whatman No4 ﬁlter paper and DNA was later extracted by boiling
in Chelex-100 (Plowe et al., 1995).
2.3. Proportional sequencing
2.3.1. Validation
Artiﬁcial mixtures of blood infected with the ATN + MF-
resistant AS-ATNMF1 clone and AS-ATN27P (AS-ATNMF1:
AS-ATN27P) were prepared in the following proportions: 100:0,
90:10, 75:25, 50:50, 25:75, 10:90, and 0:100. A drop of blood from
each mixture was dried in ﬁlter paper. After DNA extraction, sam-
ples were subjected to PCR ampliﬁcation, using oligonucleotide
primers (sense: 50-GAG GAC GCG AAA AGG AAA G-30; antisense:
50-TCT CCT CCA CAC TAT CAG C-30) ﬂaking a G–Tmutation in nucle-
otide 1155448 of chromosome 14 of P. chabaudi, identiﬁed by
whole-genome re-sequencing and conﬁrmed to be exclusive of
the ATN + MF-resistant clone, AS-ATNMF1 (unpublished data).
The resulting PCR products were sequenced with either oligonu-
cleotide primer and the corresponding heights of the overlapping
peaks (G or T) in the sequencing chromatogram on the position
corresponding to the mutation were measured according to the
Proportional Sequencing (PS) method described by Hunt et al.
(2005). The percentages of each allele were thus calculated for both
sense and antisense sequences and the observed proportions were
plotted on a graph against the expected values (Hunt et al., 2005).
Linear regression analysis was subsequently carried out to evaluate
which of the two primers (sense or antisense) was more accurate
at determining allele proportions.
2.3.2. Within-host competition assays
Two separate assays were performed: (a) competition between
the ATN + MF-resistant clone AS-ATNMF1 and its direct progenitor
AS-ATN (AS-ATNMF1:AS-ATN); and (b) competition between AS-
ATNMF1 and the parasites passaged twenty-seven times through
untreated mice, AS-ATN27P (AS-ATNMF1:AS-ATN27P). For each
assay, artiﬁcial mixtures of each of the two clones were prepared
in saline solution under the following proportions: 100:0, 90:10,
50:50, 10:90, and 0:100. 0.1 ml of each mixture containing 106 par-
asitized red blood cells was then inoculated into groups of three
uninfected mice. The animals were left untreated and absolute par-
asite growth (% parasitaemia) was inspected in every other day, be-
tween Day 4 and Day 14 post-inoculum (p.i.). Parasite proportions
were assessed as described in Section 2.3.1, following collection of
a blood sample in ﬁlter paper on the same day as parasitaemias
were counted and expressed as the mean percentage of the three
mice for both alleles. As best correlation between the observed
and expected values was obtained by using the antisense primer
(see Section 3.1.1), only this was used for calculating allele per-
centages. In order to determine whether the relative proportion
of each clone in the mixture at each sampling day was signiﬁcantly
different to that of the starting inoculum (Day 0), statistical analy-
sis was made by Pearson’s chi-squared test.Fig. 2. Validation of the proportional sequencing method. (DNA present in artiﬁcial
mixtures of AS-ATNMF1 and AS-ATN27P parasites was analysed for the detection of
a G–T substitution in position 1155448 on chromosome 14. Analyses of DNA
sequencing electropherograms resulted in the observed proportions of the sensitive
allele calculated for both forward (A) and reverse sequences (B). The values from
both forward (A) and reverse sequences (B) are plotted against the expected values.
Tendency lines are represented in grey with corresponding R2 values.3. Results
3.1. Within-host competition assays
3.1.1. Validation of the proportional sequencing assay
A G to T mutation in position 1155448 of chromosome 14 was
identiﬁed previously in the AS-ATNMF1 clone (unpublished data).
By using PS analysis (Hunt et al., 2005) targeting this mutation, it is
possible to estimate the relative proportion of AS-ATNMF1 para-
sites present in a mixture with parasites displaying the wild-type
form of this genotype (AS-ATN or AS-ATN27P). This method hasbeen used in similar studies and has shown high level of accuracy
(Hunt et al., 2005; Cheesman et al., 2007). However, it was crucial
to verify whether the accuracy of quantifying parasite proportions
using this method was satisfactory for analysing unknown mix-
tures in this particular case. To this purpose, artiﬁcial mixtures
with known proportions of AS-ATNMF1 and the uncloned parasites
passaged twenty-seven times in absence of drug treatment, AS-
ATN27P, were prepared and analysed, as described in the Section 2.
In order to estimate the accuracy of the method to conﬁdently infer
the relative abundance of each clone in an experimental mixture,
the observed proportions were plotted against the expected pro-
portions and results were analysed by linear regression. Overall,
there was a thoroughly accurate correlation between the observed
and expected values, reﬂected by a near-linear pattern in both the
sense and antisense sequencing directions (Fig. 2). However, the
tendency lines of the expected vs observed values for each of the
primers indicated that there was a more accurate correlation with
results obtained with the antisense primer (Fig. 2B), translated by
an R2 value of 0.9987, vs R2 = 0.9956 of the sense primer (Fig. 2A).
As such, sequences in the reverse direction were chosen to esti-
mate parasite proportions in the competition experiments de-
scribed herein.
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In order to determine if the evolution of resistance to ATN + MF
could have caused any inﬂuence on the growth rate of AS-ATNMF1
in blood stages relative to its progenitor AS-ATN, ﬁve groups of
three mice each were inoculated with single clone infections
(100:0 or 0:100) or mixtures of the two parasites in different pro-
portions of 90:10, 50:50, 10:90, (AS-ATN:AS-ATNMF1). Absolute
parasitaemias and proportions of each clone were analysed for
each animal along time in absence of drug treatment.
3.1.2.1. Absolute parasite growth (% parasitaemia). Mice inoculated
with AS-ATN parasites alone (100:0) showed peak parasitaemia
of about 38% on Day 10 p.i.. In the group of mice inoculated only
with AS-ATNMF1 (0:100), parasites grew faster and reached higher
levels of parasitaemia than AS-ATN (near 63% on Day 8 p.i.)
(Fig. 3A). Albeit the fact that mice inoculated with unequal propor-
tions of AS-ATN and AS-ATNMF1 (10:90 and 90:10) showed peak
parasitaemia in the same day, percentage parasitaemia at peak
was lower in mice inoculated with 90% AS-ATN. In animals inocu-
lated with equal proportions of AS-ATN and AS-ATNMF1 (50:50), a
peak parasitaemia of 55% occurred at Day 8 p.i. with a recurrent
lower peak observed on Day 12 p.i (Fig. 3A). Collectively, we may
conclude that single infections of the resistant parasite AS-
ATNMF1 perform better than single infections of its progenitor
AS-ATN, and that mixtures where the resistant parasite predomi-
nates also display improved growth in mice.
3.1.2.2. Within-host evolution of individual clone proportions over
time. The proportions of each clone in the blood of each mouse
were measured every two days, starting 4 days p.i. DNA samples
were ﬁrst obtained from blood mixtures prior to injection into
mice (Day 0). Thus, the initial proportions of AS-ATN and AS-
ATNMF1 inoculated in each animal were determined (Day 0,
Fig. 3B–D). It was possible to verify that mice inoculated with a
higher proportion of AS-ATN (90:10) appeared to have received a
smaller proportion of AS-ATN than expected (about 79% of the
wild-type allele in the mixture) (Fig. 3C). Conversely, samples ob-
tained from the inoculum where equal proportions of the two
clones were prepared, consisted of a higher proportion of AS-
ATN, as approximately a 60:40 ratio was observed instead of the
nominal 50:50 (AS-ATN:AS-ATNMF1) (Fig. 3B). Finally, the propor-
tions of each clone in the initial inoculum of the group of mice that
received a higher proportion of AS-ATNMF1 (10:90) seem to be
consistent with the expected values (Fig. 3D).
When observing the samples obtained from mice throughout
the experiment, the presence of the wild-type allele (representing
the AS-ATN clone) decreased signiﬁcantly along time, regardless of
the starting proportion of each parasite in the mixture. In mice ini-
tially inoculated with similar proportions of each clone (nominally
50:50, but in reality 60:40), the proportion of the AS-ATN allele de-
creased from 60% on Day 0 to 30% on Day 4, with a further reduc-
tion of 10% from Day 4 to Day 6. However, from Day 6 onwards, the
proportion of each parasite remained relatively stable up to Day
14, when a further reduction in the wild-type allele again was ob-
served (12%) (Fig. 3B). When observing the animals inoculated
with the higher proportion of the wild-type AS-ATN clone
(90:10) this decrease was almost linear along time, and at Day
14 the resistant parasite AS-ATNMF1 had already outgrown its sen-
sitive progenitor AS-ATN (Fig. 3C). Samples obtained from mice
inoculated with higher proportions of AS-ATNMF1 (10:90) also
showed a decrease in the proportion of the wild-type allele (AS-
ATN), with the reduction of the AS-ATN clone below detection lev-
els by Day 10 (Fig. 3D). In conclusion, these results indicate that the
evolution of ATN + MF resistance in AS-ATNMF1 did not weaken its
ﬁtness in intra-erythocytic stages, as its growth outcompeted that
of its progenitor AS-ATN.3.1.3. AS-ATN27P + AS-ATNMF1 within-host competition assay
It has been observed that consecutive passaging of asexual
stage parasites through mice may increase parasite growth
(Mackinnon and Read, 1999; Walliker et al., 2005). Consequently,
we tested the hypothesis that any potential ﬁtness gain attained
by ATN + MF resistance could have been boosted by the fact that
AS-ATN was sub-inoculated through mouse blood several times
to obtain AS-ATNMF1. Thus, in order to determine if this could
be responsible for the apparent ﬁtness advantage of AS-ATNMF1
(Fig. 3 and previous section), blood samples of AS-ATNMF1 and
the parasites passaged twenty-seven times in absence of drug
treatment, AS-ATN27P, were prepared in different proportions of
90:10, 50:50, 10:90, (AS-ATN27P:AS-ATNMF1) or as single clone
infections and injected into mice. Absolute % parasitaemias and
parasite proportions were determined along time in untreated
mice as above.
3.1.3.1. Absolute parasite growth (% parasitaemia). Whereas the
growth of AS-ATNMF1 and AS-ATN parasites showed marked dif-
ferences when absolute parasitaemia was evaluated (Fig. 3A), mice
inoculated only with AS-ATN27P (100:0) showed similar parasite
growth as observed for mice inoculated only with AS-ATNMF1
(0:100), with peak parasitaemias between 60% and 80% on Day 8
pi (Fig. 3E). In addition, parasite growth in the three groups of ani-
mals receiving the mixtures of the two parasites in different pro-
portions (90:10, 50:50, and 10:90) seemed to be very
approximate (Fig. 3E). Despite differences in the slope of the
growth curve observed in each case, these three groups of mice
showed peak parasitaemias on Day 8, ranging from 50% to 63%
(Fig. 3E).
3.1.3.2. Within-host evolution of individual clone proportions over
time. In order to assess the growth potential of AS-ATN27P and AS-
ATNMF1 in competition within the same host, the parasite propor-
tions in the blood of mice injected with the different mixtures of
parasites was analysed. As described above, a sample of the blood
mixture used to inoculate each group of mice was analysed, in or-
der to determine the actual proportions initially inoculated in each
group of mice (Day 0, Fig. 3F–H). In all cases, the proportion of
wild-type and mutant alleles (representing AS-ATN27P and AS-
ATNMF1, respectively) corresponded approximately to the ex-
pected values. After the inoculum, blood samples were extracted
from each mouse every two days (from Day 4 onwards) and then
analysed as described previously. The group of mice receiving an
inoculum containing a higher proportion of AS-ATN27P (90:10)
showed a slight increase in the proportion of the wild-type allele
(representing AS-ATN27P) along time, from 90% on Day 4 to about
93% on Day 10. From Day 12 onwards, however, the proportion of
the wild-type allele started to decrease, reaching 89% on Day 14
(Fig. 3G). The same pattern could be observed for the three parasite
mixtures tested. However, this pattern was more pronounced in
mice inoculated with equal proportions of AS-ATN27P and AS-
ATNMF1 (50:50), where there was an increase in the proportion
of the AS-ATN27P allele from about 53% on Day 4 to almost 70%
on Day 8. On Day 10, the proportion began to decrease and reached
about 50% on Day 14 (Fig. 3F). Mice inoculated with higher propor-
tions of AS-ATNMF1 (10:90) showed the same pattern of increase
of the wild-type allele (AS-ATN27P) along time. On Day 8, the pro-
portion of AS-ATN27P parasites started to increase, reaching about
25% on Day 12. On Day 14, however, there was a decrease to about
half the value measured on Day 12 (about 13%) (Fig. 3H).
In conclusion, regardless of the AS-ATN27P sensitive parasite’s
apparent tendency for improved growth at the beginning of the
infection, the ATN + MF-resistant parasite AS-ATNMF1, displayed
a growth recovery in the later stages of the mixed infection and
the relative proportions of each parasite returned to the initial
Fig. 3. Within-host competition assays between the artesunate + meﬂoquine-resistant AS-ATNMF1 clone and sensitive parasites, AS-ATN or AS-ATN27P. Animals were
inoculated with different proportions of each clone. Absolute parasite growth (percentage (%) parasitaemias) was determined along time with initial percentage of AS-ATN or
AS-ATN27P inoculated into each group of mice indicated in A and E, respectively. Represented in the bar charts are the percentages of each allele throughout the course of the
14 day infection after injection of artiﬁcial mixtures of each clone corresponding to proportions of the resistant parasite:sensitive parasite of 50:50 (B and F), 10:90 (C and G)
and 90:10 (D and H). Bars represent the mean of three animals. Day 0 corresponds to samples obtained from the blood mixture used to inoculate each mouse. Statistical
analysis was made comparing the obtained proportions along time against the proportion inoculated into mice using Pearson’s chi-squared test. ⁄p < 0.005. Samples from
mice inoculated with 100% of each of the different clones were also assayed by DNA sequencing to serve as controls. As expected, only single clone infections were detected
(data not shown).
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that there is no pronounced difference in intra-erythrocytic ﬁtness
between the sensitive and the ATN + MF-resistant parasites.4. Discussion
The choice of the most appropriate treatment for malaria is a
key public health issue for endemic countries. The ﬁtness of
drug-resistant malaria parasites has been a subject of interest be-
cause if resistant mutants are at a disadvantage in polyclonal infec-
tions with sensitive parasites, they will gradually wane as active
drug pressure is ceased. Thus, ‘‘old drugs’’ with restored efﬁcacy
could be re-introduced adding up to the already limited antimalar-
ial therapeutic arsenal. The best studied example is that of chloro-
quine (CQ), where ﬁeld studies have largely suggested that
resistant parasites were less ﬁt than sensitive ones after the drug
had been withdrawn (Kublin et al., 2003; Mita et al., 2004; Laufer
et al., 2006; Temu et al., 2006; Ord et al., 2007; Babiker, 2009;
Babiker et al., 2009). However, the same type of information about
artemisinin derivatives and ACTs is absent, because studies as
above for CQ can only be made retrospectively. Here, we carried
out a predictive study, showing that P. chabaudi malaria parasites
that are resistant to the ACT version of ATN + MF do not carry a ﬁt-
ness disadvantage relative to their ancestors in vivo. In fact, when
the resistant parasites AS-ATNMF1, were grown in competition
with their direct progenitors AS-ATN, they exhibited improved
growth performance, indicating they had actually attained a ﬁtness
advantage during the evolution of resistance. These observations
appear to deviate from the generally accepted hypothesis under
which mutations that are associated with resistance to antimalar-
ial drugs stray from the optimum biochemistry and are thus likely
to be unfavourable in the absence of drug pressure (Felger and
Beck, 2008). We consider three different explanations (not mutu-
ally exclusive) to explain the relative growth advantage of the
AS-ATNMF1-resistant parasites relative to their direct ancestors,
AS-ATN.
The ﬁrst possibility relates to the concept that natural selection
generally acts against the changes induced by mutation and the
resistant parasites should be at a disadvantage in an environment
where sensitive forms co-exist (Felger and Beck, 2008). Though
this generally accepted hypothesis is biologically coherent, it is
contingent on the existence of sensitive forms (clones) to displace
resistant clones under a within-host competition scenario.
However, depending on the historical drug selection evolutionary
background of the parasite population being studied, ‘‘entirely
drug-sensitive’’ clones may be frequently absent. Such is the case
of the present model, where the ancestors of the ATN +MF-resistant
parasites are not drug-sensitive in deﬁnition, since they were pri-
marily derived through sequential in vivo selection of pyrimeth-
amine, chloroquine and artesunate resistance (Fig. 1). Thus, we
have to consider the prospect that the growth of AS-ATN could
have already been compromised before ATN + MF selection, due
to pre-existing drug resistance-induced ﬁtness impairment. Under
this scenario, the parasite’s ﬁtness could have been restored fol-
lowing the evolution of resistance and this would explain the im-
proved growth performance of AS-ATNMF1. Importantly, the
present ﬁndings may echo on natural parasite populations of
P. falciparum, where competition is also more likely to take place
between related parasites resistant to different drugs because
resistance to most antimalarials is common in the vast majority
of endemic regions. In particular, we consider the present model
especially pertinent to South-East Asian populations of P. falcipa-
rumwhere drug resistance is widespread and artesunate resistance
appears to be emerging (Carrara et al., 2009; Dondorp et al., 2009;
Lim et al., 2010; Phyo et al., 2012), and consequently, within-hostcompetition between drug–resistant parasites is likely to be a fre-
quent event.
The other possibility to explain the improved growth of AS-
ATNMF1 is that the evolution of ATN + MF resistance itself could
have been met with selection of mutations that are not directly in-
volved in the mechanism of resistance, but compensate for any po-
tential ﬁtness loss incurred by resistance, as has been widely
reported in prokaryotes (Maisnier-Patin and Andersson, 2004;
Nilsson et al., 2006) and also suggested to happen in malaria par-
asites (Walliker et al., 2005; Osman et al., 2007). Indeed, experi-
mental work has shown an increase in ﬁtness of drug-resistant
mutants when compared with their sensitive progenitors after
subjecting malaria parasites to consecutive sub-inoculations
through mice (Mackinnon and Read, 1999; Walliker et al., 2005).
Since AS-ATNMF1 was generated by repetitive sub-inoculations
in presence of drug pressure, and these consecutive rounds of
selection could have been responsible for the increase in ﬁtness ob-
served in these parasites when compared to the original AS-ATN
clone, we carried out competition experiments between AS-
ATNMF1 and AS-ATN27P (the parasite which was derived from
AS-ATN through 27 untreated passages). In this case, we did not
observe a signiﬁcant difference in growth between the two para-
sites, leading to speculate that during the evolution of resistance
to ATN + MF, the ﬁtness of AS-ATNMF1 may have been boosted
by prolonged maintenance of the parasites in the host’s blood
which resulted in selection of compensatory mutations allowing
fast growth.
Lastly, we also contemplate the chance that prolonged mainte-
nance of parasites in the blood of the host per se, ends up increas-
ing the parasite’s ﬁtness possibly through continuous adaptation of
the parasite to the host’s pressures, such as immunity.
Resistance to the different component drugs of ACTs has been
associated with ampliﬁcation of MDR1 both in P. falciparum and
in rodent malaria parasites (Price et al., 1997, 1999, 2004; Pickard
et al., 2003; Alker et al., 2007; Wongsrichanalai and Meshnick,
2008; Lim et al., 2009; Rogers et al., 2009; Chavchich et al., 2010;
Chaijaroenkul et al., 2010; Ding et al., 2011; Borges et al., 2011).
It is of interest that AS-ATNMF1 carries a duplication of the mdr1
gene (that also translates in the gene’s overexpression) that is ab-
sent in the sensitive forms (Rodrigues et al., 2010). The metabolic
expenditure is likely to be higher in MDR1-overexpressing para-
sites as the increasing requirement of ATP that is hydrolysed by
P-glycoproteins is expected to be metabolically unfavourable to
the resistant parasites. Previous in vitro studies in P. falciparum
have conformed to the notion thatmdr1 ampliﬁcation reduces par-
asite ﬁtness (Preechapornkul et al., 2009; Chen et al., 2010). How-
ever, in contrast to those studies, in the present work this
ampliﬁcation does not seem to have a negative impact on the par-
asite’s ﬁtness in vivo. There are however, several differences be-
tween those studies and the present report that can account for
the contradictory observations, including parasite species used
(P. falciparum vs P. chabaudi), experimental background (in vitro
vs in vivo) and drug used (MF + artelinic acid vs ATN + MF). Never-
theless, we conclude that mdr1 ampliﬁcation may not universally
result in ﬁtness cost for resistant parasites and suggest that the
outcome may depend on the ancestor parasite genetic background
before the evolution of resistance and on whether further muta-
tions may compensate for mdr1-incurred ﬁtness loss.
In conclusion, we made use of a rodent malaria model to carry
out a predictive study that indicated that parasites resistant to the
ACT version of ATN + MF are not at a disadvantage in vivo during
the blood stages of the life-cycle, relative to their ancestors. Fur-
thermore, ampliﬁcation of the mdr1 gene did not prejudice growth
of the resistant parasites. Although we recognise that there are
limitations to the present work (namely that (i) an experimental
model parasite was used that may not parallel the biology of
346 L. Rodrigues et al. / Infection, Genetics and Evolution 14 (2013) 340–346human malarias and (ii) the parasite’s ﬁtness during the exoeryth-
rocytic stages was not evaluated) this study is to our knowledge,
the ﬁrst to provide insights into the within-host dynamics between
ACT-resistant and sensitive parasites, and may thus provide impor-
tant biological clues for future optimisation of treatment policies in
malaria-endemic countries.Acknowledgments
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